Evolus (EOLS) Short-term Investments (2019 - 2020)
Evolus (EOLS) posted Short-term Investments of $5.0 million for Q4 2020, down 80.0% on a QoQ basis from $25.0 million in Q3 2020, and down 74.89% year-over-year from $19.9 million in Q1 2020.
Evolus (EOLS) Short-term Investments (2019 - 2020) Analysis & Trends
Evolus' Short-term Investments history runs 2 years deep, the most recent figure standing at $5.0 million for Q4 2020.
- Quarterly Short-term Investments fell 74.89% year-over-year to $5.0 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $5.0 million (down 74.89% YoY) and the FY2020 annual result came in at $5.0 million, down 74.89% from the prior year.
- Short-term Investments was $5.0 million for Q4 2020 at Evolus, down from $25.0 million in the prior quarter.
- Across five years, Short-term Investments topped out at $79.3 million in Q1 2019 and bottomed at $5.0 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Evolus | 390.47 Mn | 340.68 Mn | 48.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 5.00 Mn |
| Sep 30, 2020 | 25.00 Mn |
| Jun 30, 2020 | 54.98 Mn |
| Mar 31, 2020 | 64.99 Mn |
| Dec 31, 2019 | 19.91 Mn |
| Sep 30, 2019 | 34.91 Mn |
| Jun 30, 2019 | 69.64 Mn |
| Mar 31, 2019 | 79.31 Mn |